Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity.
Harold E BaysPlamen KozlovskiQing ShaoPieter ProotDeborah KeefePublished in: Obesity (Silver Spring, Md.) (2020)
Licogliflozin produced significant reductions in body weight versus placebo. However, the magnitude of weight reduction was modest.